Fuse Diagnostics raises 1.6M pounds in seed investment round

Research Money Social

Molecular diagnostics startup Fuse Diagnostics has announced the successful completion of an oversubscribed seed investment round in which it raised a total of 1.6 million pounds ($2 million) from a group of angel investors and the agency Innovate UK.

In a statement, Fuse said that the funding will be used to accelerate the development of low-cost, rapid, point-of-need tests.

"We are bringing gold standard laboratory performance into small, low-cost, disposable tests that anyone can use -- with results in under 10 minutes, thanks to our proprietary ultra-rapid amplification chemistries,” Dr. Harry Lamble, CEO of Fuse, said. "The simple product format enables users to test on demand in any location -- all they have to do is apply the sample and wait for the clear visual result."

Fuse is developing two diagnostics testing platforms: its Flip range, aimed at industrial, food, and water testing, where the elimination of pathogen contamination is critical, as well as the bioprocessing industry and cell biology research; and its Apex range, aimed at clinical diagnostics and veterinary applications, as well as more advanced industrial testing.

Brothers Harry and Ralph Lamble co-founded the Cambridge, U.K.-based company following the acquisition of their firm Sense Biodetection by Sherlock Biosciences in 2023.

Page 1 of 8
Next Page